Bladder cancer laboratory findings

Jump to: navigation, search

Bladder cancer Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Bladder cancer from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Staging

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

CT

MRI

Electrocardiography or Ultrasound

Other Imaging Findings

Other Diagnostic Studies

Biopsy

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Bladder cancer laboratory findings On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Bladder cancer laboratory findings

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Bladder cancer laboratory findings

CDC on Bladder cancer laboratory findings

Bladder cancer laboratory findings in the news

Blogs on Bladder cancer laboratory findings

Directions to Hospitals Treating Bladder cancer

Risk calculators and risk factors for Bladder cancer laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Steven C. Campbell, M.D., Ph.D. Associate Editor(s)-in-Chief: Farima Kahe M.D. [2], Shanshan Cen, M.D. [3]

Overview

Laboratory findings consistent with the diagnosis of bladder cancer include blood in the urine and abnormal cells in urine cytology. [Tumor marker]] tests include ladder tumour–associated antigen (BTA), uclear matrix proteins (NMP) and mucin and carcinoembryonic antigen (CEA).

Laboratory Findings

  • Laboratory findings consistent with the diagnosis of bladder cancer include:[1][2][3]
  • Complete blood count
  • Hematuria
  • Urine cytology
  • Abnormal cells in the urine
  • Bladder tumour–associated antigen (BTA)
  • Nuclear matrix proteins (NMP)
  • Mucin and carcinoembryonic antigen (CEA)

References

  1. Shariat SF, Karam JA, Lotan Y, Karakiewizc PI (2008). "Critical evaluation of urinary markers for bladder cancer detection and monitoring". Rev Urol. 10 (2): 120–35. PMC 2483317. PMID 18660854.
  2. Villicana P, Whiting B, Goodison S, Rosser CJ (June 2009). "Urine-based assays for the detection of bladder cancer". Biomark Med. 3 (3): 265. doi:10.2217/bmm.09.23. PMC 2819730. PMID 20161673.
  3. Grossfeld GD, Litwin MS, Wolf JS, Hricak H, Shuler CL, Agerter DC, Carroll PR (April 2001). "Evaluation of asymptomatic microscopic hematuria in adults: the American Urological Association best practice policy--part I: definition, detection, prevalence, and etiology". Urology. 57 (4): 599–603. PMID 11306356.

Linked-in.jpg